Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

http://www.wikidata.org/entity/Q34463276

about

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis Transcranial brain parenchymal sonography in neurodegenerative and psychiatric diseases Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.Neuroimaging in pre-motor Parkinson's disease MDS research criteria for prodromal Parkinson's disease.The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.History of Illicit Stimulant Use Is Not Associated with Long-Lasting Changes in Learning of Fine Motor Skills in Humans.Biomarkers in Parkinson's disease: Advances and strategies.Is there a need to redefine Parkinson's disease?Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.The Concept of Prodromal Parkinson's Disease.Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity.3D transcranial ultrasound as a novel intra-operative imaging technique for DBS surgery: a feasibility study.Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls.Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.Sonography for diagnosis of Parkinson disease-from theory to practice: a study on 300 participants.Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease.Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease.Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.Predictors of Parkinson's disease--not quite sound.Structural abnormality of substantia nigra induced by methamphetamine abuse.Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.Prevalence of Prodromal Parkinson's Disease as Defined by MDS Research Criteria among Elderly Patients Undergoing Colonoscopy.Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.Cognitive changes in prodromal Parkinson's disease: A review.Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data.Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression.Transcranial Sonography in Neurodegenerative Diseases with Cognitive Decline.Midbrain raphe hypoechogenicity in migraineurs: An indicator for the use of analgesics but not triptans.Autonomic dysfunction in subjects at high risk for Parkinson's disease.Prediction of Parkinson's disease subsequent to severe depression: a ten-year follow-up study.Hand function is impaired in healthy older adults at risk of Parkinson's disease.Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults.Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.[Helpful instrumental examinations in idiopathic Parkinson's disease].Light pigmentation phenotype is correlated with increased substantia nigra echogenicity.

P2860

Q26738357-6B0FE002-D9D9-4086-965F-C8DBE3FFB304 Q27004240-45D128E0-871D-4876-8E31-789338F552D8 Q27026684-9D69025F-A3C1-4929-963B-332BAF5788A8 Q28553194-643B231E-1D0B-48F0-A7B5-2F75208324DF Q33676222-4E14C1A6-8741-4D42-B1CD-C757FE675AED Q34498279-9C812705-ED20-42BA-9A32-E44CC60B3B53 Q36332532-B4DAE9EA-2F4E-4280-81A5-9B2279854EC0 Q36447218-51A89324-5E19-4A99-9CCB-23DCF449444B Q37431507-0090FCF9-DCD8-4B8D-86E0-DAFF88D66A39 Q38110209-15A0C1B2-AC54-45B1-9574-8C512CD706B7 Q38384109-27879B43-FE0C-4DEB-9404-8B9DEF62E1BF Q38501869-53370B89-91EF-4D92-822B-05F9754E6FB0 Q38612230-66F13C3B-1E9B-4CB3-8CF0-CFB7828F7186 Q38645895-135A2A62-B812-49B3-BDD9-6479BEBD8A46 Q39019480-310519FB-6DAD-4D27-B6A7-28921ECE0425 Q39202020-074DE211-7684-4BFB-8C13-95AA17E13DA6 Q41752929-E819D108-1728-4E8A-AA4A-5F5E6FD6C4CA Q43440868-65F9AE31-3B59-4554-A7DF-A1A3C4B12328 Q45245196-6322216C-068B-4E0C-95E4-3C932A8DE355 Q45303272-00C74FEC-3409-46CC-8487-F2D18314DD9B Q45337355-07966269-301D-4434-A434-5118E3DB1299 Q45428915-A56557E5-9EA3-45D7-B8DD-7DF7F9C2E2BE Q46608874-F5E64544-0D4C-46F5-BCA0-49EB5B8908DF Q47693643-44B518F1-1DC9-40F0-8832-DFD8B6F0B6F0 Q47730775-F990B28D-9E6A-45FB-9A2D-CA58CED30470 Q47744397-653A55F3-648A-4B9C-9A0E-685ABC95E1DD Q47759449-82B14F46-1137-45D1-8677-E90B916213B1 Q47860019-2514D457-E6EF-40B0-A2FE-DA0DE90D08FF Q47964985-B53138C5-99C1-48B7-9312-D3F67F2EC6C7 Q47976362-983A4979-04F2-4F91-8DE1-F9396B0BD24E Q47986869-0687F2E8-5CAD-428C-A8FE-7359C1B6E4D7 Q48045035-75EC6A4D-7494-4E90-931A-7AB26C85DF9B Q48071243-AF701BE8-40E6-40A1-8B66-17D0C6999138 Q48214295-7D0D0E1C-CC74-4322-8E80-EA3B80F44951 Q48796961-1C5882FF-386D-4C73-B1CB-D8AFC720F3B8 Q48878610-879456FB-DA3F-4388-A4CD-D3DB064B9C51 Q48893370-8034D934-59D1-4194-ABAF-E778A7B340BE Q50240382-55BC363D-C0F3-4E68-9860-8FFEE7C1E3FE Q52148956-5876FE31-A75D-4A78-9FE6-5E756BD2040C

P2860

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

http://www.wikidata.org/entity/Q34463276

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@ast

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@en

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@nl

type

label

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@ast

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@en

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@nl

prefLabel

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@ast

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@en

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@nl

P1433

Q34463276-D8CBAA0C-27F5-482D-9EC4-59CFC9E06272

P1476

Q34463276-4A227212-D9D8-4A2E-A17E-BECE3BA215B3

P2093

Q34463276-09D41E89-2E94-4798-8763-89D14337E683

Q34463276-12C993C7-7B1D-415F-B00B-6452FFE79E17

Q34463276-144DFD9B-EE3F-4C4F-BCC4-AD57DEB2CED5

Q34463276-19B1DE96-0030-4AB5-8122-81A4DE7DAFB8

Q34463276-1B534E81-A66F-4233-8A9A-BA4E2114E046

Q34463276-1E44D002-EAAA-4663-92AF-B0B46DABEA10

Q34463276-2F43F7EE-65EC-4A68-BFE8-C0D70F3DD5BA

Q34463276-3B05B755-A6CD-4A4F-9624-80BEF6FF0ED5

Q34463276-744BDA58-76EF-43CE-9978-0CA342689C7C

Q34463276-7DDCDD2B-92DF-420B-9060-D6B126E9FB23

P2860

Q34463276-2D99B16A-910E-4A07-9D4D-99E8AE15BCFA

Q34463276-40AD3443-650D-4E34-9C58-0CF79806F537

Q34463276-4469E9F4-ADE2-4002-BBCF-7C417818E6FC

Q34463276-607C8CA4-78D1-41C3-A27E-1B1C5CD4CFBB

Q34463276-74821EFC-FE56-40F0-9700-A33A432F935E

Q34463276-8B1CC20D-2179-4BFD-922E-1C1ECE43CBCC

Q34463276-A359C9C8-C668-42E3-BED0-502007BF43F6

Q34463276-A7D4E27D-BBD7-4AB1-A91E-3E73DE833229

Q34463276-AB1BE2D4-22A9-4C09-AF48-474E1F4B8A2E

Q34463276-AE9BB8F0-9D4B-4D3F-94E3-7292AFA8E62A

P304

Q34463276-ADFF56BB-F527-45E6-9543-391A7A0F3285

P31

Q34463276-F394902B-FB8B-4C08-9F1A-D93527A34DD1

P356

Q34463276-D0268AB7-BB6A-47A0-A07E-F25601106A62

P407

Q34463276-AE4FFC58-C6BE-40D1-A4D3-A8AD366E5CD5

P433

Q34463276-997C355C-F654-42D6-9DBB-8D80C52BE623

P478

Q34463276-DE9CF1A1-33FD-45DB-8C11-3F5618A8485E

P50

Q34463276-064F6E15-9CAA-4C17-BF67-6906E36F0CDB

Q34463276-2362768F-4B41-49DF-999C-7622ECE33CE9

Q34463276-667D23D4-6951-47FB-984B-8842305DD440

Q34463276-74B9B08F-E92C-4FFE-AF36-BFAA9DE81CC6

Q34463276-7C914628-1E3C-49B9-8E78-47739D53CAAE

Q34463276-BEB90AF8-B809-4454-99C4-5AF9E5FC232F

P577

Q34463276-95871353-9A99-4116-90D4-BB4ABB968C59

P5875

Q34463276-ECFA9DFE-C443-4614-9DA4-CC2102D3011D

P698

Q34463276-AFB099C6-B85B-46CD-8579-9568D2B1E289

P921

Q34463276-5BC868E7-0525-45F2-B348-AA8FCE4F87E1

Q34463276-7721ACBE-D211-494E-A7F8-88AB5742E9D1

P356

P1433

Movement Disorders

P1476

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

@en

P2093

Alexandra Gaenslen

http://www.w3.org/2001/XMLSchema#string

Arno Gasperi

http://www.w3.org/2001/XMLSchema#string

Christoph Pausch

http://www.w3.org/2001/XMLSchema#string

Heike Stockner

http://www.w3.org/2001/XMLSchema#string

Heiko Huber

http://www.w3.org/2001/XMLSchema#string

Isabel Wurster

http://www.w3.org/2001/XMLSchema#string

Jana Godau

http://www.w3.org/2001/XMLSchema#string

Johann Willeit

http://www.w3.org/2001/XMLSchema#string

Karin Srulijes

http://www.w3.org/2001/XMLSchema#string

Kathrin Brockmann

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of Parkinson's disease

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Application of transcranial sonography in extrapyramidal disorders: updated recommendations.

Transcranial sonography in movement disorders.

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

Erectile function and risk of Parkinson's disease.

TCS in monogenic forms of Parkinson's disease.

Association of olfactory dysfunction with risk for future Parkinson's disease.

The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.

Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT.

P304

216-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25192

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Inga Liepelt-Scarfone

Philipp Mahlknecht

P577

2012-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232745715

http://www.w3.org/2001/XMLSchema#string

P698

23115051

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

substantia nigra